Every year, insurance plans update the list of drugs that they cover, also known as their formulary. That means that some drugs covered this year won’t be covered next year. (In fact, more and more drugs are excluded from formularies each year.) And drugs that are new to the market might be covered soon. If you rely on health insurance to pay for your medications, now’s a good time to pay attention. See More
Olysio Latest News
Get the latest updates on this drug from the GoodRx medical team
The FDA has issued a drug safety alert for direct-acting antivirals used to treat Hepatitis C. They warn that using direct-acting antivirals such as Sovaldi, Harvoni, or Zepatier can cause a reactivation of Hepatitis B in patients who have been previously infected with the virus.
The FDA gained knowledge about the reactivation of hepatitis B occurring from direct-acting antivirals through reported incidents and published literature. See More
Americans, get ready for sticker shock at the pharmacy.
In 2017, the nation’s largest insurance companies will likely exclude up to 154 different drugs from coverage. If you’re taking one of these prescriptions, your co-pay is about to go way, way up.
Last year, popular drugs including Viagra and Qsymia were dropped by major insurance plans for 2016. The trend continues this year. Almost 50 popular brand-name and generic drugs will likely no longer be covered by one of the nation’s largest prescription insurance providers. See More
The new Goodrx Top 10 Lists are in, and this time we take a look back at the end of 2015. These are the most popular and most expensive drugs in the US, and they cover all kinds of conditions from common heart and pain meds to pricey treatments for cancer and genetic disorders.
To start with—which drugs were filled the most in the last quarter of 2015?
If you’ve been following the news, huge price increases on necessary drugs like Daraprim and cycloserine may seem unusual—they both dropped in price again once people noticed and complained, right?
The unfortunate reality as that price increases happen in the pharmaceutical industry day-in and day-out. While the majority aren’t quite as dramatic as the Daraprim price hike, they happen more often than you might think. See More
It’s that time again—the new lists of covered and excluded drugs on next year’s insurance plans are out, and it doesn’t look great. For many Americans with health insurance, more than 50 popular brand-name and generic drugs may no longer be covered starting in January 2016.
Express Scripts and Caremark, companies that handles pharmacy benefits for more than 200 million Americans, are removing about 20 – 30 drugs each from their national preferred formularies at the end of 2015. See More
Our new top 10 lists are in for the most-dispensed and most expensive prescriptions in the US—take a look at these interesting updates.
Which prescriptions have been filled the most in 2015 so far?
Based on a sample of claims reported by pharmacies across the country, thyroid meds like Synthroid and levothyroxine near the top of the list, while standard heart and diabetes prescriptions lisinopril (Zestril, Prinivil), atorvastatin (Lipitor), and metformin (Glucophage) are still very frequently prescribed—no surprises there. See More
We’ve updated our lists of the Top 10 most-dispensed and most expensive prescriptions in the US, with some interesting changes from the end of 2014.
Curious about the most popular prescriptions?
Based on a sample of claims reported by pharmacies across the country, some common antibiotics, like amoxicillin (Amoxil) and azithromycin (Zithromax) top the list, along with heart meds like atorvastatin (Lipitor) and lisinopril (Zestril, Prinivil). See More
In the past year, the realm of hepatitis C treatment has been flourishing. Several new medications have received FDA approval and have changed the way we treat this often silent disease.
With the introduction of new first line treatments, slowly but surely, we will begin to see the discontinuation of many older hepatitis C treatments. Incivek was pulled by its manufacturer, Vertex Pharmaceuticals, back in October. See More
Viekira Pak was approved by the FDA on December 19, 2015 as the newest treatment for chronic hepatitis C (genotype 1), and is already available to patients. Genotype 1 is the most common in the US, affecting around 75% of Americans with the virus.
Were there any special circumstances for the approval of Viekira Pak?